Mackenzie Financial Corp Mersana Therapeutics, Inc. Transaction History

Mackenzie Financial Corp

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$2.16 - $5.94 $29,849 - $82,084	13,819 New	13,819 $61,000
Q1 2023 Apr 24, 2023	SELL	$4.0 - $7.02 $19,480 - $34,187	-4,870 Reduced 6.61%	68,822 $282,000
Q4 2022 Feb 14, 2023	BUY	$5.65 - $7.86 $416,359 - $579,219	73,692 New	73,692 $431,000
Q1 2020 May 14, 2020	BUY	$4.41 - $9.28 $466,472 - $981,601	105,776 New	105,776 $616,000

121

116M

233K

457K

Ticker MRSN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,169,296
Market Cap $198M
Description
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...

Get notified when there are updates to the investment portfolio of Mackenzie Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Mackenzie Financial Corp with notifications on news.